Tiziana Life Sciences plc TLSA 深 沪
已收盘 08-08 16:00:00 美东时间
2.20
+0.110
+5.26%
华盛通- 最 高2.26
- 今 开2.09
- 成交量 22.74万股
- 最 低 2.08
- 昨 收 2.09
- 总市值 2.57亿
- 52周最高 2.60
- 市盈率 静 --
- 换手率 0.19%
- 52周最低 0.6295
- 委 比 -89.30%
- 总股本 1.17亿
- 历史最高 12.15
- 量 比 0.49
- 振 幅 8.61%
- 历史最低 0.41
- 每 手 1
- 风险率 0.23%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Tiziana Life Sciences Announced Immunologic Findings From The Treatment Of A Moderate Alzheimer's Disease Patient With Intranasal Foralumab
Transcriptional analysis of white blood cells before and after foralumab therapy revealed profound immune modulatory effects. Significant changes were observed in CD4 cells, CD8 cells, and monocytes, underscoring the
07-21 19:02
Tiziana Life Sciences Announces Immunologic Analysis of Nasal Foralumab in Moderate Alzheimer's Patient
Tiziana Life Sciences announced significant immunological findings from a study using intranasal foralumab, an anti-CD3 monoclonal antibody, in a moderate Alzheimer's Disease (AD) patient. The treatment showed profound immune modulatory effects, including changes in CD4 cells, CD8 cells, and monocytes, as well as reduced inflammation in microglia PET scans. Unexpectedly, it also increased phagocytosis markers in monocytes, suggesting potential am...
07-21 11:00
Tiziana shares rise on presentation date for foralumab data
Tiziana Life Sciences (NASDAQ:TLSA) shares rose on Friday after the company said that its CEO, Ivor Elrifi, will present data related to its lead drug candidate, intranasal foralumab, for the treatmen...
06-13 21:36
Tiziana Life Sciences to Present Intranasal Foralumab Findings at Bio International Convention
Tiziana Life Sciences ( ($TLSA) ) has provided an update. On June 13, 2025, Tiz...
06-13 20:58
12 Health Care Stocks Moving In Friday's Pre-Market Session
Gainers Prenetics Global (NASDAQ:PRE) shares moved upwards by 17.8% to $9.45 d...
06-13 20:11
Tiziana Life Sciences Expands Phase 2 Clinical Trial of Intranasal Foralumab with Commencement of First Patient Dosing at Weill Cornell Multiple Sclerosis Center
Tiziana Life Sciences announces the initiation of dosing at Weill Cornell Medicine Multiple Sclerosis Center for its Phase 2 clinical trial evaluating intranasal foralumab in patients with non-active Secondary Progressive Multiple Sclerosis (na-SPMS). This marks the fifth site added to the trial, which also includes Yale University, Johns Hopkins University, Brigham and Women's Hospital, and the University of Massachusetts. The Phase 2 trial aims...
06-13 14:30
Tiziana Life Sciences to Present at the Bio International Convention
Tiziana Life Sciences CEO Ivor Elrifi will present on the clinical findings of intranasal foralumab, a fully human anti-CD3 monoclonal antibody, at the Bio International Convention in Boston on June 18. Foralumab, the first fully human anti-CD3 mAb administered intranasally, targets neuroinflammatory and neurodegenerative diseases by modulating regulatory T cells. The Company is currently conducting a Phase 2 trial in non-active secondary progres...
06-13 12:30
Tiziana Life Sciences shares are trading higher after the company highlighted clinical progress for its intranasal alzheimer's therapy.
Tiziana Life Sciences shares are trading higher after the company highlighted c...
05-24 03:58
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers Tiziana Life Sciences (NASDAQ:TLSA) shares increased by 10.2% to $1.51...
05-23 05:05
Tiziana Life Sciences reports purchase of shares by chairman
Tiziana Life Sciences (NASDAQ:TLSA) on Monday said that its Executive Chairman and Founder, Gabriele Cerrone, has purchased 15,000 common shares at $1.55 per share, bringing his total holding to 43,25...
05-12 20:04
